Viewing Study NCT00444899



Ignite Creation Date: 2024-05-05 @ 5:24 PM
Last Modification Date: 2024-10-26 @ 9:31 AM
Study NCT ID: NCT00444899
Status: COMPLETED
Last Update Posted: 2019-05-01
First Post: 2007-03-07

Brief Title: Clinical and Economic Benefits of Cardiovascular Risk Management by a Dietician in Type 2 Diabetes Patients
Sponsor: Université de Sherbrooke
Organization: Université de Sherbrooke

Study Overview

Official Title: Clinical and Economic Benefits of Cardiovascular Risk Management by a Dietician in Diabetic Patients
Status: COMPLETED
Status Verified Date: 2019-04
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: GRC
Brief Summary: Worldwide health systems and practitioners are facing obesity epidemics High blood pressure dyslipidemia and diabetes prevalence will explode during the 21st century

The two main objectives of this 2-year controlled prospective study are

1 to demonstrate that for patients with high blood pressure diabetes and dyslipidemia dietician conducted survey and management in combination with annual endocrinologist follow-up enable both attainment and maintenance of recommended blood pressure glycemic and lipid goals as well as smoking cessation
2 to demonstrate that dietician management is more cost effective than conventional care provided by general practitioners and endocrinologists

Results are expected to show significantly different cardiovascular risk profiles BMI and waist circumference systolic and diastolic blood pressure LDL-C triglycerides and Total cholesterolHDL ratio HbA1c smoking between baseline and after 2 years follow-up Sample size was determined in order to show statistically significant differences between the two groups

Results will document for the benefit of care givers health economists and policy makers alike an innovative and integrated model of care which is expected to be effective at the patient level as well as cost effective with respect to the increasing financial burden of diabetes on the health system
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None